Background Evidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is thought to be an important mechanism for generating CSCs. In the present study, we investigate whether oxaliplatin-treated cancer tissues possess characteristics of CSCs, and explore oxaliplatin resistance in these tissues. Methods Hepatocellular carcinoma cells (MHCC97H cells) were subcutaneously injected into mice to form tumors, and the mice were intravenously treated with either oxaliplatin or glucose. Five weeks later, the tumors were orthotopically xenografted into livers of other mice, and these mice were treated with either oxaliplatin or glucose. Metastatic potential, sensitivity to oxaliplatin, and expression of CSC-related markers in the xenografted tumor tissues were evaluated. DNA microarrays were used to measure changes in gene expression as a result of oxaliplatin treatment. Additionally, an oxaliplatin-resistant cell line (MHCC97H-OXA) was established to assess insulin-like growth factor 1 secretion, cell invasion, cell colony formation, oxaliplatin sensitivity, and expression of CSC-related markers. The effects of an insulin-like growth factor 1 receptor inhibitor were also assessed. Results Oxaliplatin treatment inhibited subcutaneous tumor growth. Tumors from oxaliplatin-treated mice that were subsequently xenografted into livers of other mice exhibited that decreasing sensitivity to oxaliplatin and increasing pulmonary metastatic potential. Among the expression of CSC-related proteins, the gene for insulin-like growth factor 1, was up-regulated expecially in these tumor tissues. Additionally, MHCC97H-OXA cells demonstrated that increasing cell invasion, colony formation, and expression of insulin-like growth factor 1 and CSC-related markers, whereas treatment with an inhibitor of the insulin-like growth factor 1 receptor suppressed these effects. Conclusion Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1.
References
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP (2010) Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 15 Suppl 434–41. doi: 10.1634/theoncologist.2010-s4-34
[3]
Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127: S179–188. doi: 10.1053/j.gastro.2004.09.032
[4]
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118–1127. doi: 10.1056/nejmra1001683
[5]
Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, et al. (2008) Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol 31: 317–322. doi: 10.1097/coc.0b013e318162f57d
[6]
Yang AD, Fan F, Camp ER, van Buren G, Liu W, et al. (2006) Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147–4153. doi: 10.1158/1078-0432.ccr-06-0038
[7]
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, et al. (2007) Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629–3637. doi: 10.1245/s10434-007-9583-5
[8]
De Larco JE, Wuertz BR, Manivel JC, Furcht LT (2001) Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 61: 2857–2861.
[9]
Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, et al. (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277–283. doi: 10.3892/ijo.31.2.277
[10]
Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, et al. (2010) Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer 10: 219. doi: 10.1186/1471-2407-10-219
[11]
Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, et al. (2008) Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 68: 516–520. doi: 10.1158/0008-5472.can-07-3063
[12]
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, et al. (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012–1024. doi: 10.1053/j.gastro.2008.12.004
[13]
Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9: 50–63. doi: 10.1016/j.stem.2011.06.005
[14]
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153–166. doi: 10.1016/j.ccr.2008.01.013
[15]
Liu LL, Fu D, Ma Y, Shen XZ (2011) The power and the promise of liver cancer stem cell markers. Stem Cells Dev 20: 2023–2030. doi: 10.1089/scd.2011.0012
[16]
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275–284. doi: 10.1038/nrc1590
[17]
Jordan CT, Guzman ML (2004) Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23: 7178–7187. doi: 10.1038/sj.onc.1207935
[18]
Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, et al. (2000) Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403–4411.
[19]
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
[20]
Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C (2012) Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol 227: 2947–2952. doi: 10.1002/jcp.23041
[21]
Ford NA, Nunez NP, Holcomb VB, Hursting SD (2013) IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. Endocr Relat Cancer 20: 39–51. doi: 10.1530/erc-12-0329
[22]
Png KJ, Halberg N, Yoshida M, Tavazoie SF (2012) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481: 190–194. doi: 10.1038/nature10661
[23]
Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364–6370. doi: 10.1158/1078-0432.ccr-07-4879
[24]
Adhami VM, Afaq F, Mukhtar H (2006) Insulin-like growth factor-I axis as a pathway for cancer chemoprevention. Clin Cancer Res 12: 5611–5614. doi: 10.1158/1078-0432.ccr-06-1564
[25]
Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625–638. doi: 10.1016/j.beem.2008.08.004
[26]
Lee J, Ju J, Park S, Hong SJ, Yoon S (2012) Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of beta-catenin signaling in hormone refractory PC-3 prostate cancer cells. Nutr Cancer 64: 153–162. doi: 10.1080/01635581.2012.630161
[27]
Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 53: 160–170. doi: 10.1002/hep.24000
[28]
Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, et al. (2010) Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28: 1930–1939. doi: 10.1002/stem.521
[29]
Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, et al. (2010) Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31: 1376–1380. doi: 10.1093/carcin/bgq120
[30]
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, et al. (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81: 814–821.
[31]
Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416–423. doi: 10.1038/nm843
[32]
Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, et al. (2005) Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11: 8557–8563. doi: 10.1158/1078-0432.ccr-05-0944
Xiao Y, Isaacs SN (2012) Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum albumin (BSA)–not all BSAs are alike. J Immunol Methods 384: 148–151. doi: 10.1016/j.jim.2012.06.009
[35]
Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy? J Pathol 223: 147–161. doi: 10.1002/path.2793
[36]
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339–9344. doi: 10.1158/0008-5472.can-06-3126
[37]
Li Z (2013) CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2: 17. doi: 10.1186/2162-3619-2-17
[38]
Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749–1758. doi: 10.1038/sj.onc.1210811
[39]
Tong CM, Ma S, Guan XY (2011) Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 26: 1229–1237. doi: 10.1111/j.1440-1746.2011.06762.x
[40]
Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, et al. (2010) Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70: 6945–6956. doi: 10.1158/0008-5472.can-10-0785
[41]
Lu J, Ye X, Fan F, Xia L, Bhattacharya R, et al. (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23: 171–185. doi: 10.1016/j.ccr.2012.12.021
[42]
Sica A, Larghi P, Mancino A, Rubino L, Porta C, et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349–355. doi: 10.1016/j.semcancer.2008.03.004
[43]
Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, et al. (2012) Herbal Compound “Songyou Yin” Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid Based Complement Alternat Med 2012: 908601. doi: 10.1155/2012/908601
[44]
Werner H, Bruchim I (2009) The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58–71. doi: 10.1080/13813450902783106
[45]
Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, et al. (2009) Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol 34: 329–338. doi: 10.3892/ijo_00000155
[46]
Bitelman C, Sarfstein R, Sarig M, Attias-Geva Z, Fishman A, et al. (2013) IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett.
[47]
Sun Y, Zheng S, Torossian A, Speirs CK, Schleicher S, et al. (2012) Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys 82: e563–572. doi: 10.1016/j.ijrobp.2011.06.1999
[48]
Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12: 589–603. doi: 10.1517/14728222.12.5.589
[49]
Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20–47. doi: 10.1210/er.2006-0001
[50]
Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12: 90–100. doi: 10.1038/sj.cgt.7700775
[51]
Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, et al. (2007) An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 13: 6429–6439. doi: 10.1158/1078-0432.ccr-07-0648
[52]
Brabletz T (2012) EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22: 699–701. doi: 10.1016/j.ccr.2012.11.009
